FDA Extends Leqembi Review and Grants Cell Therapy a Second Chance

Summary

The Food and Drug Administration has delayed its decision on a more convenient, under-the-skin version of the Alzheimer's medication Leqembi. Regulators were evaluating whether patients could use this injectable version as an initial therapy. Now, the agency has pushed its decision back three months to August 24. The delay provides the FDA time to review a major amendment to the application, though regulators have not raised any specific concerns about the drug's chances of approval.

In a separate regulatory shift, the FDA is offering a second chance to a cell therapy called Ebvallo. Developed by Pierre Fabre, the therapy has already faced two rejections. Now, the agency has agreed to let the company resubmit its application based on an ongoing late-stage clinical trial. Instead of using a concurrent control group, this trial will compare patient outcomes against historical data. The submission is still pending updated results with more patients and a longer period of follow-up.

Meanwhile, Blackstone Life Sciences is investing $250 million in Anagram Therapeutics to fund an experimental treatment called ANG003. The oral medication is designed for exocrine pancreatic insufficiency, a condition where the pancreas fails to produce enough essential digestive enzymes.

Why it matters.

These updates highlight a broader industry push toward making treatments more manageable for patients. An under-the-skin version of Leqembi could make starting Alzheimer's treatment much more accessible than requiring patients to travel to clinics for intravenous infusions. Similarly, Anagram's experimental enzyme therapy could drastically improve daily life for people with pancreatic conditions. Patients currently face a massive burden, sometimes needing to take up to forty pills a day just to digest their food.

While the prospect of a simpler pancreatic treatment is exciting, it is important to note that ANG003 remains in early-stage development and is only just preparing to start Phase 2 clinical trials. However, the massive financial backing from Blackstone signals strong confidence in the future of therapies that prioritize patient convenience.

From the source

The story in numbers.

Blackstone Life Sciences investment in Anagram Therapeutics: $250 million
FDA review delay for subcutaneous Leqembi starting dose: 3 months
Maximum pills per day in current exocrine pancreatic insufficiency regimens: 40

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

FDA Extends Leqembi Review and Grants Cell Therapy a Second Chance

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.